Blue Medicare Medical Policies

Notification of Policy Revisions Effective October 1, 2020 (Posted June 30, 2020)

Medical Policy Revision
Pegloticase (Krystexxa®) "Notification" New policy developed. Krystexxa is considered medically necessary for the treatment of adult patients with chronic gout when specified medical criteria and guidelines are met. Added HCPCS code J2507 to Billing/Coding section. References added. Medical Director review 6/2020. Notification given 6/30/2020 for effective date 10/1/2020.